

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

0202120
Licensee

315536
In accordance with letter dated **July 1, 2006,**
and facsimile dated July 26, 2006,

1. Emma L. Bixby Medical Center
Department of Radiology
2. 818 Riverside Avenue
Adrian, MI 49221

3. License number 21-03194-01 is amended in its entirety to read as follows:

4. Expiration date **September 30, 2014**

5. Docket No. 030-02027
Reference No.

6. Byproduct, source, and/or special nuclear material

7. Chemical and/or physical form

8. Maximum amount that licensee may possess at any one time under this license

A. Any byproduct material permitted by 10 CFR 35.100

A. Any

A. As needed

B. Any byproduct material permitted by 10 CFR 35.200 excluding xenon-133

B. Any

B. As needed

C. Any byproduct material permitted by 10 CFR 35.300

C. Any

C. As needed (not to exceed 1 curie of iodine-131)

D. Any byproduct material permitted by 10 CFR 31.11


D. Any

D. As needed

E. Any byproduct material permitted by 10 CFR 35.400

E. Any

E. 3.0 curies total



Any
Repackaged Kits
Source: Bard
Therapy, Inc. Model
STM-251, and Theragenics
Corporation Model No. 200)

9. Authorized Use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300 (excluding iodine-131 for thyroid carcinoma therapy).
- D. In vitro studies.
- E. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
21-03194-01

Docket or Reference Number
030-02027

Amendment No. 38

CONDITIONS

10. A. Licensed material shall be used at the licensee's facilities located at 818 Riverside Avenue, Adrian, Michigan.
- B. Licensed material in Items 6.A. and 6.B. may be used at medical care facilities anywhere in the United States where the U.S. Nuclear Regulatory Commission maintains jurisdiction for regulating the use of material.

11. Radiation Safety Officer: **Harold A. Johnson, M.D.**

12. **Licensed material is only authorized for use by, or under the supervision of:**

- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized Users

Material and Use

Wayne S. Court, M.D.

10 CFR 35.400

Rajender K. Ahuja, M.D.

10 CFR 35.400

Chun Il Mah, M.D.

10 CFR 35.400

Gerald W. Marsa, M.D.

10 CFR 35.400

William K. Mueller, M.D.

10 CFR 35.400

Steven R. Zeidner, M.D.

10 CFR 35.400

Steven J. Rubin, M.D.

10 CFR 35.400

John Feldmeier, M.D.

10 CFR 35.400

Faheem Ahmad, M.D.

10 CFR 35.400

Harold A. Johnson, M.D.

10 CFR 35.400

Dhaval Kirit Parikh, M.D.

10 CFR 35.400

Henry R. Silverman III, M.D.

10 CFR 35.100 and 35.200 (excluding xenon-133 and aerosols)

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
21-03194-01Docket or Reference Number
030-02027

Amendment No. 38

Sean Theisen, M.D.**10 CFR 35.100 and 35.200****John E. Freitas****10 CFR 35.100, 35.200, 35.300 and 31.11**

13. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. **In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing financial assurance for decommissioning.**
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application received July 29, 2005



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date AUG 01 2006

By

James R. Mullauer, M.H.S.
Materials Licensing Branch
Region III